期刊
REVISTA BRASILEIRA DE PSIQUIATRIA
卷 33, 期 4, 页码 374-378出版社
ASSOC BRASILEIRA PSIQUIATRIA
DOI: 10.1590/S1516-44462011000400011
关键词
Bipolar disorder; Depression; Acetylcysteine; Antioxidants; Oxidative stress
类别
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil
- Stanley Medical Research Foundation
- MBF
- NHMRC
- Beyond Blue
- Geelong Medical Research Foundation
- Bristol Myers Squibb (BMS)
- Eli Lilly
- Glaxo SmithKline (GSK)
- Organon
- Novartis
- Mayne Pharma
- Servier
Objective: In this report, we aimed to evaluate the effect of add-on N-acetylcysteine (NAC) on depressive symptoms and functional outcomes in bipolar disorder. To that end, we conducted a secondary analysis of all patients meeting full criteria for a depressive episode in a placebo-controlled trial of adjunctive NAC for bipolar disorder. Method: Twenty-four week randomised clinical trial comparing adjunctive NAC and placebo in individuals with bipolar disorder experiencing major depressive episodes. Symptomatic and functional outcome data were collected over the study period. Results: Seventeen participants were available for this report. Very large effect sizes in favor of NAC were found for depressive symptoms and functional outcomes at endpoint. Eight of the ten participants on NAC had a treatment response at endpoint; the same was true for only one of the seven participants allocated to placebo. Discussion: These results indicate that adjunctive NAC may be useful for major depressive episodes in bipolar disorder. Further studies designed to confirm this hypothesis are necessary. (C) 2011 Elsevier Editora Ltda. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据